Ticker
ACARIX.ST

Price
0.83
Stock movement down
-0.01 (-1.43%)
Company name
Acarix A/S
Exchange
(ST
,
Currency
SEK
)
Sector
Healthcare >
Medical Devices
Market cap
208.88M
Ent value
152.12M
Price/Sales
47.89
Price/Book
2.42
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
-37.74%
3 year return
-20.57%
5 year return
-34.79%
10 year return
-
Last updated: 2022-08-25

DIVIDENDS

ACARIX.ST does not pay dividends

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales47.89
Price to Book2.42
EV to Sales34.87

FINANCIALS

Per share

Loading...
Per share data
Current share count251.97M
EPS (TTM)-0.22
FCF per share (TTM)-0.22

Income statement

Loading...
Income statement data
Revenue (TTM)4.36M
Gross profit (TTM)3.35M
Operating income (TTM)-54.76M
Net income (TTM)-54.85M
EPS (TTM)-0.22
EPS (1y forward)-

Margins

Loading...
Margins data
Gross margin (TTM)76.71%
Operating margin (TTM)-1255.36%
Profit margin (TTM)-1257.54%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash68.74M
Net receivables9.78M
Total current assets81.98M
Goodwill0.00
Intangible assets15.71M
Property, plant and equipment0.00
Total assets98.28M
Accounts payable629.00K
Short/Current long term debt448.00K
Total current liabilities11.81M
Total liabilities11.98M
Shareholder's equity86.31M
Net tangible assets82.33M

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-54.98M
Capital expenditures (TTM)202.00K
Free cash flow (TTM)-55.18M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-63.56%
Return on Assets-55.81%
Return on Invested Capital-63.35%
Cash Return on Invested Capital-63.73%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open0.82
Daily high0.84
Daily low0.75
Daily Volume1.58M
All-time high9.18
1y analyst estimate2.40
Beta2.24
EPS (TTM)-0.22
Dividend per share-
Ex-div date-
Next earnings date10 Nov 2022

Downside potential

Loading...
Downside potential data
ACARIX.STS&P500
Current price drop from All-time high-90.97%-12.18%
Highest price drop-94.86%-56.47%
Date of highest drop16 Mar 20209 Mar 2009
Avg drop from high-72.05%-11.38%
Avg time to new high287 days12 days
Max time to new high1428 days1805 days
COMPANY DETAILS
ACARIX.ST (Acarix A/S) company logo
Marketcap
208.88M
Marketcap category
Small-cap
Description
Acarix AB (publ), a medical technology company, develops and commercializes diagnostic tests for cardiovascular diseases in Germany, Sweden, the Middle East, Switzerland, Austria, and internationally. The company offers CADScor System, a non-invasive and ultra-sensitive analytical device for the diagnosis of coronary artery disease. Acarix AB (publ) was founded in 2009 and is headquartered in Malmö, Sweden.
Employees
0
Investor relations
-
CEO
Country
Sweden
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Press release Malmö, Sweden, June 22, 2022 Acarix partners with Strategic Health AK to roll-out CADScor®System across the state of Alaska Acarix continues its US expansion by partnering with Strategic...
June 22, 2022
Press release Malmö, Sweden, June 10, 2022 Acarix signs additional commercial agreement in US and receives order for CADScor®System in Louisiana. Acarix continues the US expansion with another commerc...
June 10, 2022
Press release Malmö, Sweden, June 3, 2022 Acarix signs additional commercial agreement in US and receives rapid orders in both Mississippi and Tennessee Acarix today announces an additional commercial...
June 3, 2022
Press release Malmö, Sweden, May 11, 2022 Announcement from Acarix's annual general meeting The annual general meeting 2022 ("AGM") of Acarix AB ("Acarix" or the "Company") was held today on 11 May 20...
May 11, 2022
Press release Malmö, Sweden, May 11, 2022 Acarix AB (publ) publishes Interim Report, January – March 2022 Increased commercial momentum and great interest in CADScor® System on the US market2022 has s...
May 11, 2022
Press release Malmö, Sweden, May 6, 2022 Acarix presents at Naventus Health Care Summit 2022 Helen Ljungdahl Round, President and CEO of Acarix AB (publ), will present at the Naventus Health Care Summ...
May 6, 2022
Press release Malmö, Sweden, April 20, 2022 Acarix publishes the annual report for 2021 Today, Wednesday April 20, Acarix is publishing its Annual Report for 2021 on the company website www.acarix.com...
April 20, 2022
Notice of Annual General Meeting in Acarix AB The shareholders of Acarix AB, reg. no. 559009-0667, (the "Company"), are hereby convened to the annual general meeting to be held on Wednesday 11 May 202...
April 11, 2022
Press release (MAR)Malmö, Sweden, April 1, 2022 FDA requests supplementary information for Acarix breakthrough designation request for heart failure diagnosis The Food and Drug Administration (FDA) ha...
April 1, 2022
Press release (MAR)Malmö, Sweden, March 11, 2022 Acarix receives strategic order for the CADScor®System in US Acarix today announces first order of the CADScor®System in the US from Apex Heart and Vas...
March 11, 2022
Next page